D de Jong1, N S Macklon, B C Fauser. 1. Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
Abstract
OBJECTIVE: To study whether minimal interference in the process of selection of the single dominant follicle may serve as the basis for a simplified ovarian stimulation regimen for IVF. DESIGN: Single-center randomized pilot study. SETTING:Tertiary referral fertility center. PATIENT(S): Fifteen normo-ovulatory patients with a regular indication for IVF. INTERVENTION(S): Ovarian stimulation for IVF was begun with 100 or 150 IU/d recombinant FSH starting on cycle day 5. From cycle day 8 or later, cotreatment was begun with 0.25 mg/d GnRH antagonist. No luteal support was provided. MAIN OUTCOME MEASURE(S): Total number of dominant follicles and characteristics of the endocrine cycle. RESULT(S): Multiple follicle development occurred in five of eight patients in the 100-IU group and in all seven women in the 150-IU group. Follicular phase and luteal phase lengths were normal, but the endocrine profile was abnormal. CONCLUSION(S): A fixed daily dose of 150 IU recombinant FSH starting in the midfollicular phase resulted in ongoing growth of a restricted number of dominant follicles and sufficient oocytes retrieved to lead to ET. A marked reduction in the total amount of gonadotropins administered compared with standard treatment was achieved. Withholding luteal support did not exclude pregnancies.
RCT Entities:
OBJECTIVE: To study whether minimal interference in the process of selection of the single dominant follicle may serve as the basis for a simplified ovarian stimulation regimen for IVF. DESIGN: Single-center randomized pilot study. SETTING: Tertiary referral fertility center. PATIENT(S): Fifteen normo-ovulatory patients with a regular indication for IVF. INTERVENTION(S): Ovarian stimulation for IVF was begun with 100 or 150 IU/d recombinant FSH starting on cycle day 5. From cycle day 8 or later, cotreatment was begun with 0.25 mg/d GnRH antagonist. No luteal support was provided. MAIN OUTCOME MEASURE(S): Total number of dominant follicles and characteristics of the endocrine cycle. RESULT(S): Multiple follicle development occurred in five of eight patients in the 100-IU group and in all seven women in the 150-IU group. Follicular phase and luteal phase lengths were normal, but the endocrine profile was abnormal. CONCLUSION(S): A fixed daily dose of 150 IU recombinant FSH starting in the midfollicular phase resulted in ongoing growth of a restricted number of dominant follicles and sufficient oocytes retrieved to lead to ET. A marked reduction in the total amount of gonadotropins administered compared with standard treatment was achieved. Withholding luteal support did not exclude pregnancies.
Authors: D de Jong; M J C Eijkemans; N G M Beckers; R V Pruijsten; B C J M Fauser; N S Macklon Journal: J Assist Reprod Genet Date: 2002-12 Impact factor: 3.412
Authors: Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon Journal: Drugs Date: 2004 Impact factor: 9.546
Authors: Sarah F Lensen; Jack Wilkinson; Jori A Leijdekkers; Antonio La Marca; Ben Willem J Mol; Jane Marjoribanks; Helen Torrance; Frank J Broekmans Journal: Cochrane Database Syst Rev Date: 2018-02-01